Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01795911 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
A Phase 2 study of Hepatitis C, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 1
- Study location
NCT01795911 is a Phase 2 study of Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 165 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01795911, a Phase 2 study of Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
Substudy C: The purpose of this substudy is to determine whether Lambda combined with Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment naïve subjects with genotype 1b chronic HCV infection
Conditions Studied
Interventions
- BIOLOGICAL Pegylated Interferon Lambda
- DRUG Ribasphere
- DRUG Daclatasvir
Study Locations (1)
Texas
- Alamo Medical Research - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01795911
The ClinicalTrials.gov registry entry for NCT01795911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (91% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Pegylated Interferon Lambda is the first listed.
NCT01795911 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01795911 about?
NCT01795911 is a clinical study titled "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin". Substudy C: The purpose of this substudy is to determine whether Lambda combined with Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment naïve subjects with genotype 1b chronic HCV infection
What is the current status of trial NCT01795911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2013-03. Estimated completion is 2014-09.
What conditions does trial NCT01795911 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT01795911?
The interventions under investigation include: Pegylated Interferon Lambda (BIOLOGICAL), Ribasphere (DRUG), Daclatasvir (DRUG).
Who is sponsoring clinical trial NCT01795911?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01795911 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.